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Summary    
 
Objective 
 
Researchers need to be confident about the reliability of epidemiological studies that quantify 
medication use through self-report. Some evidence suggests that psychiatric medications are 
systemically under-reported. Modern record linkage enables validation of self-report with 
national prescribing data as gold standard. Here, we investigated the validity of medication 
self-report for multiple medication types.  
 
Study Design and Setting 
Participants in the Generation Scotland population-based cohort (N=10,244) recruited 2009-
11 self-reported regular usage of several commonly prescribed medication classes. This was 
matched against Scottish NHS prescriptions data using three- and six-month fixed time 
windows. Potential predictors of discordant self-report, including general intelligence and 
psychological distress, were studied via multivariate logistic regression.  
 
Results 
Antidepressants self-report showed very good agreement (κ=0.85, (95% Confidence Interval 
(CI) 0.84-0.87)), comparable to antihypertensives (κ=0.90, (0.89-0.91)). Self-report of mood 
stabilizers showed moderate-poor agreement (κ=0.42 CI 0.33-0.50). Relevant past medical 
history was the strongest predictor of self-report sensitivity, whereas general intelligence was 
not predictive.  
 
Conclusion 
In this large population-based study, we found self-report validity varied among medication 
classes, with no simple relationship between psychiatric medication and under-reporting. 
History of indicated illness predicted more accurate self-report, for both psychiatric and non-
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psychiatric medications. Although other patient-level factors influenced self-report for some 
medications, none predicted greater accuracy across all medications studied. 
 
 
Keywords 
 
Agreement;  Pharmacoepidemiology; Self-report; Medicines; Indication; Linkage 
 
Word Count:  3927 words  
 
 
 
WHAT IS NEW 
 
• Self-reported medication use shows high validity in the general population 
although there is variation between medication classes. 
• A simple relationship between psychiatric medications and under-reporting was 
not found. Mood stabilizers show moderate-poor agreement, due to both under-
report and false positives, whereas antidepressant reporting is comparable to 
other long-term non-psychiatric medications.  
• Medical history of an indicated health condition is the strongest predictor of 
accurate report. General intelligence was not associated with the accuracy of 
reporting. 
• Medication-related factors such as range of indications, prescribing cycles, and 
phrasing of self-report question may also influence accuracy of self-report.  
• When matching self-report to prescribing data, longer fixed time windows 
produce higher levels of agreement and positive predictive values, at the expense 
of some loss of sensitivity.  
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1 Introduction 
 
Cohort studies, and other epidemiological studies using self-reported data, depend on the 
accuracy of the self-report to make accurate and reliable conclusions. This includes 
pharmaco-epidemiological and large-scale biobanking studies which are based on self-
reported medication use. Self-reported medication use can be determined by questionnaire [1, 
2]; by telephone or internet survey[3]; or by face-to-face interview[4-7]. However, self-report 
is subject to recall errors and biases[8, 9] and patients may be less willing to disclose details 
of certain medications than others.  
 
The accuracy of self-report can be verified by comparison to a trusted measure or “gold 
standard”. For medication utilization, the choice of gold standard depends to an extent on the 
purpose of the study (i.e. estimating patient adherence, or monitoring prescribing behaviour of 
clinicians), and there is therefore no universally applicable and accepted gold standard [10] 
[11]. One option is for a third party to perform a home inventory [12] or record individual 
medications produced by the patient [13], but these assessments are difficult to perform on a 
large scale. An alternative is to compare self-report data to prescriptions, healthcare insurance 
claims, or general practice medical records [4, 5, 11, 14].  Prescribing databases have been 
shown to be highly accurate in recording medication utilization [15], at least for those 
medications that require prescriptions.  
 
Among published studies comparing medication self-report to prescribing data, the majority 
have been relatively small in size[4, 6, 7, 10-13, 16-18]. Many studies are restricted to certain 
medications or medication types, such as antihypertensives [11]; cardiovascular drugs [6];  
antidepressants [17], or hormone replacement therapy [1]; or to special populations, such as 
the elderly [6, 12, 15]; postmenopausal women [2, 5]; or psychiatric illnesses [16]. Few 
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studies utilize large population-based samples[4, 13, 14, 19] or multiple disparate medication 
types[13, 19-21]. Such comparisons are important, however, for they enable study of 
systematic over- and under-reporting of medication utilization between drug classes. 
 
Self-report can be compromised by a number of factors, including not understanding the 
question, poor recall, and intended non-disclosure[4]. There is no consensus on patient-level 
factors predisposing to discordance between medication self-report and gold standard 
measures, but previous reports have implicated advancing age[9, 19], being unmarried [19, 
21],  number of medications regularly dispensed[18, 22], suffering poor health [19], and 
lower educational attainment[21]. Within medication classes, there is some evidence that 
psychiatric medications are less likely to be accurately self-reported[19, 22]. Potential 
explanations for this include confusion regarding medication indication but also non-
disclosure due to social desirability bias[9] or self-stigmatization[2, 4, 10, 23].  Factors that 
have not to date been found to influence reporting include gender[19, 21] and cognitive health 
[21]. 
 
Prescribing data can be sourced from local health providers or insurers[10], pharmacy records 
[6, 11, 13, 14, 17, 21], social insurance databases [16, 19] or national health service databases 
[1, 2, 4]. The recording of the dispensing and collection of medication, as well as its 
prescribing, is important for studies that seek to measure patient utilization (although even 
collection of a medication is not a hard indicator of usage). The country of origin of the study, 
and respective prescription legislation, dispensing and reimbursement practices, are also 
relevant to interpreting self-report against prescribing data (for example, over-the-counter 
medications may not appear in this data), and to making comparisons between national 
studies.  
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In this study, we sought to ascertain agreement between medication self-report, derived from 
a large UK cohort study, compared to record-linked national prescribing data as gold 
standard, across a range of commonly used psychiatric and non-psychiatric medications. We 
hypothesised that agreement would be lower for psychiatric medication types, due to systemic 
under-reporting. To our knowledge this is one of the largest population-based studies of 
medication self-report also incorporating a covariate analysis method across a range of 
medications.  
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2 Method 
2.1 Study Population 
Our study utilized the Generation Scotland: Scottish Family Health Study (GS:SFHS) family- 
and population-based cohort of Scottish adult volunteers (n=21,474), recruited February 
2006-March 2011, which has been described elsewhere[24, 25]. The cohort has a higher 
proportion of females (59%) and older median age (47 males: 48 females) than the Scottish 
population at the 2001 census (37 and 39 respectively) [25, 26].  Written informed consent 
was obtained for 98%of GS:SFHS for data linkage to routinely collected healthcare records.  
2.2 Medication Self Report Data 
 
All participants in GS:SFHS were asked to complete a pre-clinic questionnaire prior to their 
enrolment in the study. The first phase of the study used a text-based questionnaire which is 
not part of this analysis. Those individuals recruited between June 2009 – March 2011 
(n=10,980, 59.5% female) completed a coded questionnaire where the Medications section 
was a “Yes” versus “No” checkbox, with the accompanying question “Are you regularly 
taking any of the following medications?”. The available options were: (1) “Cholesterol 
lowering medication (e.g. Simvastatin)” (2) “Blood pressure lowering medication” (3) 
“Insulin” (4) “Hormone replacement therapy” (5) “Oral contraceptive pill or mini pill” (5) 
“Aspirin”  (6)“Antidepressants” (7) “Mood stabilizers”. The completed questionnaires were 
then machine read and electronically recorded using anonymised patient linkers.  
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2.3 Additional Covariate Data 
 
Additional sociodemographic information collected in the questionnaire included gender, age, 
educational attainment, smoking status and relationship status. Compared to the rest of GS, 
our sample was moderately older and contained more individuals with no school 
qualifications and also more degree level educated individuals (Table 1, Figure 1). Lifetime 
history of affective disorder (major depression and bipolar disorder) was obtained using the 
Structured Clinical Interview for DSM-IV Disorders (SCID)[25]. Self-reported history of 
hypertension, heart disease and diabetes was recorded. In addition, during the GS interview a 
variety of cognitive tests were performed [24], including digit symbol from the Wechsler 
Adult Intelligence Scale III [27], logical memory from the Wechsler Memory Scale III[28] 
and verbal fluency[29]. From these tests, we derived a measure of general intelligence (g) as 
the first un-rotated principle component, explaining 44% of the variance in scores. [30, 31] 
Psychological distress was measured using the General Health Questionnaire-28(Likert 
scoring)[32]. 
 
2.4 Prescribing Data and Linkage 
 
All Scottish citizens registered with a General Practitioner (more than 96% of the population) 
are assigned a unique identifier (Community Health Index (CHI) number). This was 
employed to record link GS:SFHS questionnaire data to the national Prescribing Information 
System (PIS) administered by NHS Services Scotland Information Services Division [33]. 
PIS is a database of all Scottish NHS prescriptions for payments for medications prescribed 
by GPs; nurses; dentists; pharmacists; and hospitals where the medication was dispensed in 
the community. There is no prescription charge in Scotland.  Hospital dispensed prescriptions 
and over-the-counter medications are not included. Patient level data has been available in 
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PIS since April 2009 [34]. We obtained PIS prescribing data for April 2009-March 2011. We 
used the dates of dispensing, not prescription, when matching to self-report.   
 
2.5 Matching Prescribing to Self-Report 
 
For each individual and medication type, concordance with GS:SFHS self-report was checked 
against PIS prescribing record dispensing dates within a “fixed time window” [2, 4, 14, 
16]including the month of questionnaire completion, and two months preceding (total three 
months), and also five months preceding (total six months). The majority of prescriptions, 
including in Scotland, are dispensed in quantities of 90 days duration or less[13, 35]. A 
previous Dutch study [12] also found that fixed time windows shorter than 90 days are less 
sensitive, although the generalizability of this finding is uncertain. Accordingly, we employed 
two fixed time windows, three and six months duration, in order to assess their relative 
benefits in terms of agreement, sensitivity and positive predictive value.  
 
To ensure all individuals had at least six months of potentially available prescribing records, 
we restricted analysis to GS:SFHS participants who had completed their medication 
questionnaire in September 2009 or later. This equated to 10, 244 participants (6065 females 
and 4179 males) enrolled September 2009-March 2011 (Table 1, Figure 1). Of these, 96.5% 
had medication records available (the remainder were presumably not using prescribed 
medication) which compared to 95.6% for the whole GS cohort.  
 
The PIS data allows medications to be identified by approved drug name and/or associated 
British National Formulary[36] paragraph code. Medication indication is not recorded. Our 
matching criterion for each medication type is detailed in Table 4(Supplementary).  
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2.6 Missing Data 
 
The self-report questionnaire employed a ‘Yes’/’No’ checkbox, but some individuals ticked 
neither box (or data was otherwise missing, Table 2). In our main analysis we treated each 
medication separately, excluding the missing self-report values for each case. However, to 
mitigate the potential of hereby introducing biases, or not accounting for individuals who 
intended to deny medication use by leaving the section blank, we conducted two additional 
analyses – one with all individuals with any missing data excluded(n=7836), and the other 
with missing data coded as denial of medication use (Table 5, Supplementary).  
 
 
2.7 Statistical Analysis 
 
All analyses were carried out using R version 3.2.3[37]. Level of agreement between self-
report and prescribing data was ascertained using Cohen’s kappa (κ) method of rating inter-
observer variation [38].  Kappa scores of <0.40 were considered fair to poor; 0.41-0.60 
moderate; 0.61-0.8 substantial; and >0.81 good or better [39, 40]. We also calculated 
sensitivity, specificity and positive predictive values(PPV). Ninety five percent confidence 
intervals(CI) were included.  
 
We performed multivariate logistic regression analysis on predictors of false negative self-
report compared to true positive (sensitivity). Due to some covariate missing data, the sample 
size of this analysis was reduced to 9043 for complete case analysis(Table 1, Figure 1). Odds 
ratios with 95% CI were calculated. Multiple testing was adjusted for using the False 
Discovery Rate method with significance level (alpha) 0.05. As Generation Scotland is a 
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partly family-based cohort, we adjusted for any correlation due to family relatedness using the 
Generalized Estimating Equations method[41]. 
 
3 Results 
 
Of the 10,244 individuals in the study, 6164 (60.17%) ticked ‘No’ to every medication 
question (Figure 1). In addition, 485 (4.74%) left blank or had missing data for every 
question. The proportion of completed responses differed between medications and was 
greatest for antihypertensives (86.44%) and lowest for mood stabilizers (77.87%, χ2 =256.07, 
p<2.2E-16)(Table 2). The most commonly prescribed medication (six-month window) was 
antihypertensives, prevalence 19.05%, whereas antidepressants prevalence was 12.22% and 
mood stabilizers 1.32%. The prevalence of lifetime history of affective disorder in our sample 
was 12.66%(n=1297) for major depressive disorder and 0.31% for bipolar disorder(n=32).  
The self-reported prevalence of hypertension was 12.66% (n=1297), heart disease 3.37% 
(n=345) and diabetes 3.15% (n=323) (Table 1). 
 
3.1 Agreement and Validity 
 
Agreement (Table 2, Figure 2) between medication self-report and prescribing data was 
generally very good across medication classes. Greatest agreement was found for cholesterol 
lowering medication (κ=0.95, CI 0.94-0.96) (6-month fixed time window unless otherwise 
stated). Agreement for antidepressants (κ=0.85, CI 0.84-0.87) was lower than 
antihypertensives (κ=0.90, CI 0.89-0.91) but still within the highest kappa banding of >0.81. 
By contrast, agreement for mood stabilizers was moderate-poor (κ=0.42, CI 0.33-0.50). 
Comparing the six-month fixed time window to three-month, κ scores were higher, although 
only to a degree beyond 95% confidence intervals in the case of HRT and oral contraceptives.  
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Self-report sensitivity (Table 2, Figure 2) was slightly reduced in the six-month time window 
versus three-month, but was still greater than 0.80 for all medications except mood stabilizers. 
Antidepressant sensitivity (0.85, CI 0.82-0.87) was comparable to antihypertensives (0.86, CI 
0.85-0.88). Sensitivity for mood stabilizers was comparatively poor (0.40, CI 0.31-0.50) 
indicating a high rate of false negatives.  
 
The positive predictive value (Table 2, Figure 3) for antidepressant use (0.89, CI 0.87-0.91) 
was substantial, albeit less than antihypertensives and cholesterol lowering drugs, and 
contrasted with modest PPV for mood stabilizers (0.45 CI 0.35-0.56). The six-month fixed 
time window significantly improved PPV for most medication groups, with greatest effect for 
HRT and oral contraceptives (which nevertheless showed relatively moderate PPV in both 
time windows).   
 
3.2 Predictors of Failure To Self-Report Medication Usage 
 
Multivariate logistic regression (Table 3) found no covariates universally associated, across 
all medications, with failure to self-report medication usage, as determined by the prescribing 
data gold standard. General intelligence (g) was not associated with increased false negatives 
for any medication. Psychological distress (GHQ) reduced odds of false negatives for 
antidepressants (OR 0.98, CI 0.96-1.00, pFDR 0.081) and mood stabilizers(OR 0.96 CI 0.91-
1.01, pFDR 0.197), but this relationship was not significant for multiple testing.  
 
There was reduced discordant self-reporting for several medications if the patient had a 
history of an illness for which that medication was indicated,  such as affective disorder and 
mood stabilisers (OR 0.09, CI 0.02-0.35 pFDR 0.005), and hypertension and antihypertensives 
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(OR 0.04, CI 0.02-0.06 pFDR>0.001). Similar associations were found for affective disorder 
and antidepressants, and cardiac disease and aspirin, with p values of >0.1 after correcting for 
multiple testing.  
 
Age and gender showed no consistent association, although older age was associated with 
lower false negatives for antihypertensives, antidepressants and possibly aspirin(pFDR 0.074), 
and female gender was associated with increased false negatives for antihypertensives (OR 
1.75, CI 1.16-2.62, pFDR 0.020).  
 
3.3 Influence of Missing Data 
 
Recoding missing data as negative self-report (Table 5, Supplementary) resulted in somewhat 
lower levels of agreement and lower sensitivities for all medications. However, agreement 
remained good for antidepressants (κ=0.81 CI 0.79-0.83) and poor for mood stabilisers (0.34 
CI 0.26-0.41). There was a demonstrable reduction in sensitivity for antidepressants (0.78 CI 
0.75-0.80) but this reduction was not confined to psychiatric medications, being found also in 
antihypertensives (0.79 CI 0.77-0.81).  
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4 Discussion  
 
In this population-based cohort, we found substantial to very good agreement between 
medication self-report and electronic prescribing records, for most medications studied. We 
hypothesised that psychiatric medications would show less agreement and systematic under-
reporting. Agreement for mood stabilizers was indeed considerably worse, although we found 
evidence of both under- and over-reporting(false positives). However, for antidepressants the 
agreement, sensitivity and PPV were broadly comparable to other medications studied. We 
did not identify any generalizable single predictors of failure to self-report prescribed 
medications, for psychiatric medications or for medications generally. However, past medical 
history of an indicated health condition showed the strongest effect in promoting self-report 
accuracy across classes, and this was also true for psychiatric medications.  
 
In general, the six-month fixed time window outperformed the three-month for agreement and 
PPV, at the expense of modest loss of sensitivity. This was most evident for HRT and oral 
contraceptives in women, which could imply these medications are dispensed in longer time 
cycles, and require longer fixed time windows relative to other medications.  
 
4.1 Predictors of Discordant Self-Report 
 
We found that a medical history of an indicated health condition for a given medication, such 
as affective disorder for mood stabilizers, or hypertension for antihypertensives, reduced the 
odds of false negatives. If systematic under-reporting of psychiatric medications due to self-
stigma was taking place, we might have expected to find the reverse. Relationship status and 
educational status did not predict discordance, except in the case of mood stabilizers where 
lack of school qualifications was associated with false negative reporting. This could indicate 
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reduced understanding of the definition of “mood stabilizer” among the less educated, but 
might also represent association between lesser educational achievement and use of 
medications (such as antipsychotics) included in our definition of mood stabilizers.  
 
We found that general intelligence (g) did not influence concordance of medication self-report 
with prescribing data, which to our knowledge has not been previously reported. We also 
believe we are the first to investigate psychological distress and medication self-report. 
Interestingly, while psychological distress might be posited as a potential factor in under-
reporting psychiatric medications (e.g. through self-stigma), we found some evidence of a 
relationship between the increased GHQ score and greater sensitivity of self-reporting of 
antidepressants (p<0.1). Gender was not generally associated with accuracy, except in the 
case of antihypertensives, where increased odds of false negatives (OR 1.75 CI 1.16-2.62) 
were found, perhaps indicating greater usage of these medication types for non-
antihypertensive purposes among females. 
 
4.3 Questionnaire Phrasing  
One possible explanation for the poor agreement, sensitivity and PPV for mood stabilizers is 
confusion among questionnaire respondents about the meaning of “mood stabilizer”. There is 
no consensus definition of mood stabilizer among clinicians,[42] and laypersons may 
therefore be unsure as to its meaning. Klungel[8] has previously reported that sensitivity of 
medication self-report is influenced by the specificity of question phrasing. In our matching to 
prescribing data we employed a broad definition of mood stabilizers, but when a narrower 
definition (excluding antipsychotics) was employed the agreement was even worse(κ=0.29, 
CI 0.20-0.38).  
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4.4 Comparison With Other Studies 
 
Table 6(Supplementary) describes the agreement of this present study, using the 6-month 
fixed time window, with other large published studies. We report a higher level of agreement 
(κ=0.86) for antidepressants than Nielsen (κ=0.66)[4], Rauma (κ=0.65) [2] and Noize 
(κ=0.81)[20]. When making comparisons with studies performed in other healthcare systems, 
it is important recognise the variations between countries in prescribing legislation and access 
to medication. Scotland has a national health system, with no prescription charges, and 
prescribing data is collated nationally, which might explain a higher concordance with self-
report and prescribing data than might be possible in some comparator studies.  
 
Kwon[10] compared survey antidepressant self-report in a longitudinal depression study 
(n=164) with pharmacy claims data and a three-month fixed window and found substantial 
levels of agreement (κ=0.69). Interestingly, where there were discrepancies in prescription 
record antidepressant use, they found on notes review that most cases could be explained by 
antidepressants being used for other indications, or due to recent discontinuation. In our 
study, we attempted to minimise the rate of antidepressant false positives due to other 
indications by excluding amitriptyline from our searches (amitriptyline is widely prescribed 
but now rarely for depression in the UK).  
 
With regard to mood stabilizers, a recent study comparing self-reported medication use in a 
genetic study of schizophrenia (n=905) [16] found substantial levels of agreement (κ=0.74) 
between self-report of mood stabilizers and an administrative prescription database. This is a 
much higher level of agreement than found in our study, although we note that Haukka’s was 
not a community-based sample and had a much higher prevalence of mood stabilizer use. A 
comparison of a postal medication survey (n=11,031) with national prescription records 
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reported by Rauma[2] found substantial levels of agreement for antidepressant reporting 
(κ=0.65) but poor agreement (κ=0.30) for other psychoactive medications, a result more 
comparable with our own findings.  
 
4.5 Study Strengths and Weaknesses  
 
 
Our study used a large (n=10,244) population-based cohort linked to high fidelity Scottish 
PIS records (capture rate in excess of 95%)[34]. Self-report was via a short, simply worded 
questionnaire which obviated interviewer bias and did not require long-term recall of 
medication use. Response rate was high. We employed a variety of methods to compare the 
two data sources over two fixed time windows and performed covariate analysis of predictors 
of discordant self-report.  
 
However, our method of verifying medication utilization took no account of dose and 
concordance with medication was assumed. Patients may be prescribed a drug but not fill 
their prescription (primary noncompliance), although our use of date of dispensing rather than 
prescribing date would have obviated this to an extent, it would still be unknown if the 
dispensed drug was collected. In addition, patients may not take the drug, or not take as 
intended (secondary noncompliance), and concordance can be as low as 50% for 
antidepressants and antihypertensives[4, 43].  In addition, the questionnaire referred to 
“regularly” taken medication whereas our method recorded any prescription within the fixed 
time window as positive use. The absence of data in PIS on medication indication increased 
the risk of over-inclusion and false positives, particularly for medications with broader 
indications, although we attempted to decrease this using our exclusion criteria (Table 4, 
Supplementary). Fixed time windows also potentially record false positives for medications 
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discontinued during the window, but prior to self-report, although this is more common with 
medications taken acutely, such as antibiotics[12].  
 
We must therefore concede that prescription data is by its nature an imperfect gold standard, 
although its use enables very large sample sizes which improve overall accuracy. The use of 
prescribing data as a gold standard involves some strong assumptions, including that the 
patient could not have obtained the medication without it being recorded in the prescribing 
data. The extent to which this is true depends on a variety of variables, including the 
medication type, prescribing legislation of the country of study, and the movement of 
individual patients between healthcare providers. Indeed, some studies are performed on the 
basis of self-report as gold standard to analyse the validity of clinical or prescribing 
records[44].   However, the advantage of prescribing data as a gold standard is that it is an 
objective measure, with definitions of medication usage that can be readily replicated across 
studies and countries (whereas self-report questionnaires can vary considerably in definition 
and interpretation), which can be utilised at large scale across multiple medication types, and 
that is not subject to potential recall and desirability biases of self-report studies[45].  
 
Data linkage is also a fast-moving field, and though the PIS data from 2011 we used in this 
study had high fidelity and a capture in excess of 95%, future studies using larger datasets and 
more complex linkage may enable even more accurate estimates of validity. For example, as 
data linkage improves, cross referencing to other sources of clinical data such as GP and 
hospital records should assist identifying true cases and also reduce the incidence of false 
positives for those who have discontinued medication through the time windows analysed.  
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As discussed, the use of the term “mood stabilizer” may have caused confusion. Many 
individuals did not tick either checkbox, and response rate differed between medication types, 
from 86.44% for antihypertensives to 77.87% for mood stabilizers. This may have reflected 
variations in understanding of, or willingness to answer, the question, and could have biased 
our results or inflated the kappa scores. However, we demonstrated that recoding this missing 
data as denial of use still produced substantial levels of agreement (Table 5, Supplementary). 
The Cohen’s kappa method itself may inflate values depending on the proportion of subjects 
in each category[46], hence we have also tabulated the raw proportions (Table 7, 
Supplementary). GS:SFHS is a partly family-based cohort and this could potentially have 
introduced some correlation bias into our analysis, although we accounted for this in our 
multivariate regression through Generalized Estimating Equations.   
 
 
4.6 Conclusion 
 
Our study provides convincing evidence that medication self-report is accurate compared to 
prescribing data, particularly for medication classes that are more precisely definable. We 
have shown that self-report of antidepressant use meets the highest threshold for Cohen’s 
kappa agreement and can be considered valid for research and clinical purposes. Our analysis 
of potential patient-level predictors of reporting discordance, such as gender, age, education 
and general intelligence, did not identify generalizable factors across all medication classes, 
although there was some evidence that medical history of an indicated condition improves 
sensitivity of self-report. As discussed above, medication-level factors such as range of 
possible indications, and length of dispensing cycles, may also be important when validating 
self-report  across a fixed time window with prescribing data as gold standard.  
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Our study also demonstrates the utility of record linkage of longitudinal population based 
cohorts to nationally administered prescribing datasets, as a useful adjunct to epidemiological 
and large biobanking studies. Utilising administrative health data for verification and quality 
control of self-report has applications beyond epidemiological studies and can be potentially 
exploited in clinical applications, such as data-linked clinical support tools acting as adjuncts 
to clinical interview, and in formulating predictive models of disease risk.[47]   
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Table 1.  Socio-demographic, clinical and cognitive characteristics of study populations compared to whole Generation Scotland cohort.  
      
 GS:SFHS   
(N=21474) 
 
 
Individuals in the current study 
(N=10244) 
 
Subset of individuals in current study 
used in complete case multivariate 
logistic regression analysis (N=9043) 
 
Female 12674 (59.02%)  6065 (59.21%)  5329 (58.9%) 
Age 18-39 6769 (31.52%)  3072(29.99%) †  2797(30.93%) ‡ 
Age 40-64 12346 (57.49%)  6015 (58.72%) †  5304(58.65%) 
Age 65-99 2359 (10.99%)  1157(11.29%)  942(10.42%) 
Affective Disorder (SCID) 2848 (13.26%)  1329 (12.97%)  1159 (12.82%) 
Diabetes (Self-Report) 659 (3.07%)  323 (3.15%)  277 (3.06%) 
Hypertension(Self-
Report) 
2836 (13.21%)  1297 (12.66%) †  1125 (12.44%) 
Cardiac Disease(Self-
Report) 
777 (3.62%)  345 (3.37%) †  284 (3.14%) ‡ 
No School Certificate 2452 (11.42%)  1432 (13.98%) †  1296 (14.33%) ‡ 
Postgraduate Education 6323 (29.44%)  3273 (31.95%) †  3164 (34.99%) ‡ 
Smoker 3662 (17.05%)  1733 (16.92%)  1484 (16.41%) ‡ 
Relationship Status - 
Single 
6720 (31.29%)  3236 (31.59%)  2866 (31.69%) ‡ 
      
GHQ Likert Score 16 (8.87)  15.73 (8.74) †  15.66 (8.69) ‡ 
Wechsler Logical 
Memory Test I &II 
30.7 (8.48)  30.95(8.15)  31.17 (8.05) ‡ 
Mill-Hill Vocabulary Test 30.06 (4.76)  30.09 (4.66)  30.23 (4.62) ‡ 
Wechsler Digit Symbol 
Substitution Task 
72.23 (17.22)  71.71 (17.15) †  72.52 (16.88) ‡ 
Verbal Fluency Test 39.71 (11.72)  39.89 (11.70) †  40.22 (11.65) ‡ 
 
Abbreviations: GS:SFHS, Generation Scotland : Scottish Family Health Study. GHQ, General Health Questionnaire.  
All values are totals with percentages, unless shown in italics where they are means with standard deviations in parentheses. 
† = Significant differences (alpha=0.05) between Generation Scotland and Study Population as determined by Chi square / t tests.  
‡ = Significant differences (alpha=0.05) between Study Population and subset used in multivariate logistic regression analysis as determined by Chi square / t tests. 
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Table 2. Medication self-report and prescribing data prevalences, agreements, sensitivities, specificities and positive predictive values, measured on 
two fixed time windows – 3 months and 6 months duration respectively – in the current study (n=10,244, including 6065 females) 
     
3 MONTH FIXED TIME WINDOW 
 
6 MONTH FIXED TIME WINDOW 
  
Total (n) 
completed 
question,  
with Yes or 
No (%) 
 
Medication 
prevalence 
according 
to self 
report (%) 
 
Medication 
prevalence 
according 
to PIS (%)* 
 
Agreement 
κ (95% CI) 
 
Sensitivity 
(95% CI) 
 
Specificity 
(95% CI) 
 
Positive 
predictive 
value 
(95% CI) 
 
Agreement 
κ (95% CI) 
 
Sensitivity 
(95% CI 
 
Specificity 
(95% CI) 
 
Positive 
predictive 
value 
(95% CI) 
Antidepressant**  8333 
(81.35) 
9.60 10.10 0.84  
(0.82-0.86) 
0.90  
(0.87 – 
0.92) 
0.99  
(0.99-0.99) 
0.90  
(0.87-0.92) 
0.85  
(0.84-0.87) 
0.85  
(0.82-0.87) 
0.99  
(0.99-0.99) 
0.89  
(0.87-0.91) 
Mood stabilizer *** 7977 
(77.87) 
1.17 1.32 0.40  
(0.31-0.49) 
 
0.41  
(0.31-0.52) 
 
0.99  
(0.99-0.99) 
 
0.41  
(0.31-0.52) 
 
0.42  
(0.33-0.50) 
 
0.40  
(0.31-0.50) 
 
 
0.99  
(0.99-1.00) 
 
0.45  
(0.35-0.56) 
 
 
Cholesterol lowering 
medication 
8789 
(85.80) 
13.97 13.81 0.92  
(0.91-0.94) 
0.97 
(0.96-0.98) 
 
0.98 
(0.98-0.99) 
 
0.90  
(0.88-0.92) 
 
0.95  
(0.94-0.96) 
 
0.97  
(0.95-0.97) 
 
0.99  
(0.99-0.99) 
 
0.95  
(0.94-0.97) 
 
Antihypertensive 8855 
(86.44) 
16.85 19.05 0.90  
(0.89-0.91) 
0.89  
(0.87-0.91) 
0.99  
(0.99-0.99) 
 
0.95  
(0.94-0.96) 
 
0.90  
(0.89-0.91) 
 
0.86  
(0.85-0.88) 
 
1.00 
 (0.99-1.00) 
 
0.98  
(0.97-0.98) 
 
Aspirin 8445 
(82.44) 
9.28 7.63 0.81  
(0.78-0.83) 
 
0.97  
(0.95-0.98) 
 
0.97  
(0.97-0.98) 
 
0.72 
(0.68-0.75) 
 
0.84  
(0.82-0.86) 
 
0.95  
(0.93-0.96) 
 
0.98 
 (0.97-0.98) 
 
0.78  
(0.75-0.81) 
 
Insulin 8016 
(78.25) 
1.11 0.97 0.87  
(0.82-0.93) 
 
1.00  
(0.92-1.00) 
 
1.00  
(1.00-1.00) 
 
0.78  
(0.67-0.86) 
 
0.93  
(0.89-0.97) 
 
1.00  
(0.93-1.00) 
 
1.00  
(1.00-1.00) 
 
0.88  
(0.79-0.94) 
 
HRT (female only) *4794 
(79.04) 
5.97 4.59 0.62  
(0.57-0.68) 
 
0.92  
(0.87-0.96) 
 
0.97  
(0.96-0.97) 
 
0.49  
(0.43-0.55) 
 
0.78  
(0.74-0.82) 
 
0.91  
(0.86-0.94) 
 
0.98  
(0.98-0.98) 
 
0.70  
(0.64-0.75) 
 
Oral contraceptives 
(female only) 
*4849 
(79.95) 
14.62 12.79 0.55  
(0.51-0.59) 
 
0.82  
(0.78-0.86) 
 
0.92  
(0.91-0.92) 
 
0.47  
(0.43-0.51) 
 
0.73  
(0.70-0.76) 
 
0.82  
(0.79-0.85) 
 
0.95  
(0.95-0.96) 
 
0.72  
(0.68-0.75) 
 
Abbreviations :  PIS, Prescribing Information System.    HRT, Hormone Replacement Therapy 
* Six month time window employed  
** Note that a broader definition of antidepressant than that shown in table, which included amitriptyline, returned an agreement of κ=0.83(0.81-0.85) at six month time window with sensitivity of 0.75(0.73-0.78) 
*** Note that a narrower definition of mood stabilizer than that shown in table, which comprised only lithium, sodium valproate, lamotrigine and carbamazepine, returned an agreement of κ=0.29(0.20-0.38) at 
six month time window with sensitivity of 0.21(0.22-0.43) 
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Table 3.  Odds Ratios (with 95% Confidence Intervals) For Factors Associated With Failure To Self-Report Medication Use (False Negatives) As Determined By Prescribing 
Data As Gold Standard  
 Antidepressants Mood stabilizers Cholesterol 
lowering medication 
Antihypertensives Aspirin Oral contraceptives 
(females only) 
Female sex  0.67 (0.42-1.09) 0.75 (0.24-2.33) 1.62 (0.80-3.30) 1.75 (1.16-2.62) 1.14 (0.52-2.48) - 
Age 0.97 (0.95-0.99) 0.96 (0.91-1.02) 0.95 (0.92-0.99) 0.94(0.92-0.96) 0.94 (0.90-0.99) 1.01 (0.98-1.04) 
 
      
Affective disorder 0.55 (0.35-0.87) 0.09 (0.02-0.35) 0.72 (0.22-2.42) 0.82 (0.47-1.44) 0.70 (0.19-2.51) 1.31 (0.69-2.49) 
Diabetes 
- - 0.42 (0.13-1.40) 0.30 (0.13-0.70) - - 
Hypertension  
- - 0.28 (0.11-0.71) 0.04 (0.02-0.06) 0.49 (0.23-1.06) - 
Heart disease 
- - 0.30 (0.07-1.25) 0.82 (0.45-1.50) 0.15 (0.03-0.65) - 
 
      
No school certificate  0.60 (0.26-1.32) 17.0 (2.3-125.84) 0.45 (0.12-1.72) 0.66 (0.37-1.17) 0.88 (0.28-2.82) 0.65 (0.07-5.89) 
Higher education 1.17 (0.70-2.00) 1.27 (0.25-6.35) 1.63 (0.65-1.09) 0.85 (0.54-1.34) 1.27 (0.44-3.64) 1.41 (0.80-2.49) 
Smoker 0.90 (0.52-1.54) 0.12 (0.02-0.082) 1.30 (0.45-3.76) 1.84 (1.09-3.11) 1.58 (0.59-4.21) 1.98 (1.13-3.46) 
Ex-Smoker 0.66 (0.38-1.11) 0.44 (0.10-2.00) 1.32 (0.59-2.92) 1.40 (0.93-2.12) 0.71 (0.28-1.81) 1.18 (0.65-2.14) 
Relationship status - 
couple 
0.89 (0.56-1.41) 2.03(0.59-7.01) 1.31 (0.58-2.97) 0.96 (0.63-1.47) 0.91 (0.40-2.08) 0.78 (0.48-1.28) 
 
      
General intelligence (g) 0.85 (0.70-1.04) 0.76 (0.46-1.26) 0.85 (0.65-1.11) 1.02 (0.85-1.21) 1.17 (0.83-1.66) 0.92 (0.74-1.15) 
Psychological distress 
(GHQ Likert) 
0.98 (0.96-1.00) 0.96 (0.91-1.01) 0.99 (0.95-1.04) 0.99 (0.97-1.01) 1.00 (0.95-1.04) 1.02 (0.99-1.04) 
       
Significant associations are shown in bold (alpha=0.05 and adjusted for multiple testing by False Discovery Rate method) and near-significant associations (alpha >0.10) are shown in italics.  
The following factors were used as controls and do not appear in the table : male sex; age 18-39; secondary school education only; no affective disorder found on SCID; no history of self- 
reported high blood pressure/heart disease/diabetes; smoking status –never smoked; relationship status –single. 
Insulin and hormone replacement therapy (HRT) are not shown in the table as no significant associations with predictors were found.  
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Figure 1.  Flowchart of derivation of study population, and subset used in logistic regression analysis, from the 
Generation Scotland cohort.  
 
Abbreviations :  GS = Generation Scotland; PIS = Prescribing Information System; CHI = Community Health Index 
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Figure 2.  Agreement and Validity of Medication Self-Report Compared With Prescribing Data As Gold Standard 
Using Three And Six Month Fixed Time Windows, With 95% Confidence Intervals  
 
Abbreviations : PPV = Positive Predictive Value;  HRT = Hormone Replacement Therapy;  OCP = Oral Contraceptive Pill.  
 
